Serum Bcl-2 concentrations in overweight-obese subjects with nonalcoholic fatty liver disease by G. TARANTINO et al.
 BRIEF ARTICLE
Serum Bcl-2 concentrations in overweight-obese subjects 
with nonalcoholic fatty liver disease
Giovanni Tarantino, Francesco Scopacasa, Annamaria Colao, Domenico Capone, Marianna Tarantino, Ernesto 
Grimaldi, Silvia Savastano
World J Gastroenterol  2011 December 28; 17(48): 5280-5288
 ISSN 1007-9327 (print)  ISSN 2219-2840 (online)
© 2011 Baishideng. All rights reserved.
Online Submissions: http://www.wjgnet.com/1007-9327office
wjg@wjgnet.com
doi:10.3748/wjg.v17.i48.5280
5280 December 28, 2011|Volume 17|Issue 48|WJG|www.wjgnet.com
Giovanni Tarantino, Department of Clinical and Experimental 
Medicine, Federico Ⅱ University Medical School of Naples, 5, 
80131 Naples, Italy
Francesco Scopacasa, Ernesto Grimaldi, Department of Bio­
chemistry and Medical Biotechnology, Federico Ⅱ University 
Medical School of Naples, 5, 80131 Naples, Italy
Annamaria Colao, Silvia Savastano, Department of Molecular 
and Clinical Endocrinology and Oncology, Endocrinology Unit, 
Federico Ⅱ University Medical School of Naples, 5, 80131 
Naples, Italy
Domenico Capone, Department of Neurosciences, Unit of Cli­
nical Pharmacology, Federico Ⅱ University Medical School of 
Naples, 5, 80131 Naples, Italy
Marianna Tarantino, Department of Biomorphological and 
Functional Sciences, Federico Ⅱ University Medical School of 
Naples, 5, 80131 Naples, Italy
Author contributions: Tarantino G conceived the study, ana­
lyzed statistical data, and wrote the manuscript; Savastano S, 
Colao A and Capone D critically revised the paper; Tarantino 
M and Tarantino G performed ultrasonography; Grimaldi E and 
Scopacasa F performed laboratory analyses.
Correspondence to: Giovanni Tarantino, MD, Department of 
Clinical and Experimental Medicine, Federico Ⅱ University 
Medical School of Naples, Via Sergio Pansini, 5, 80131 Naples, 
Italy. tarantin@unina.it
Telephone: +39­81­7462024  Fax: +39­81­5466152
Received: February 3, 2011    Revised: June 27, 2011
Accepted: October 27, 2011
Published online: December 28, 2011
Abstract
AIM: To shed some light on the relationship between 
anti-apoptotic serum Bcl-2 concentrations and metabolic 
status, anthropometric parameters, inflammation indi-
ces, and non-alcoholic fatty liver disease severity were 
investigated in 43 young individuals with fatty liver (FL) 
and 41 with nonalcoholic steatohepatitis (NASH). 
METHODS: Circulating levels of Bcl-2 were detected 
in 84 patients with ultrasonographic findings of “bright 
liver” and/or hyper-transaminasemia of unknown origin 
and/or increase in γ-glutamyl-transpeptidase (γ-GT) 
strictly in the absence of other acute or chronic liver dis-
ease, whose age was not advanced, who gave consent 
to liver biopsy and were then divided on the basis of the 
histological results into two groups (43 with FL and 41 
with NASH). Twenty lean subjects, apparently healthy 
and young, were chosen as controls.
RESULTS: Serum Bcl-2 concentrations were significant-
ly higher in the FL group than in the NASH group. Insu-
lin resistance and γ-GT activity were significantly higher 
in NASH subjects. Apoptotic hepatocytes were signifi-
cantly more numerous in NASH patients. NASH patients 
presented with larger spleens and augmented C-reactive 
protein (CRP) concentrations than healthy subjects. Ste-
atosis grade at histology was similar in both NASH and 
FL populations. The number of apoptotic cells was sig-
nificantly related to anti-apoptotic Bcl-2 protein values 
in FL patients. Bcl-2 serum levels positively correlated 
to body mass index (BMI) values (P  ≤ 0.0001) but not 
to age of the population. Triglycerides/HDL ratio corre-
lated well to waist circumference in males (P  = 0.0008). 
γ-GT activity was associated with homeostatic metabolic 
assessment (HOMA) (P  = 0.0003) and with serum fer-
ritin (P  = 0.02). Bcl-2 concentrations were not related 
to either spleen size or CRP values. NASH patients pre-
sented a weak negative correlation between lobular in-
flammation and Bcl-2 levels. A prediction by low values 
of serum Bcl-2 towards a greater presence of metaboli-
cally unhealthy overweight/obese patients (MUOs) was 
evidenced. HOMA, BMI and uric acid, in that sequence, 
best predicted serum Bcl-2 concentrations. 
 CONCLUSION: MUOs could be detected by Bcl-2 levels. 
By favoring the life span of hepatocytes, and enhancing 
triglyceride formation, the anti-apoptotic process inhibits 
free fatty acids toxicity in FL.
© 2011 Baishideng. All rights reserved.
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INTRODUCTION
High serum levels of  triglycerides/free fatty acids (FFA) 
and insulin resistance (IR) are features of  non-alcoholic 
fatty liver disease (NAFLD), an additional manifestation 
of  the metabolic syndrome[1]; the former is extremely 
common in patients suffering from overweight/obesity 
(O/O), and ranges from fatty liver (FL) to nonalcoholic 
steatohepatitis (NASH) and liver cirrhosis. In determin-
ing NASH, a role is thought to be played by FFAs that 
directly engage the core apoptotic machinery by activat-
ing the proapoptotic protein Bax, in a c-jun N-terminal 
kinase-dependent manner[2]. Moreover, increased apopto-
sis in liver specimens from NASH patients is associated 
with iron overload[3], which clearly correlates with IR and 
inflammation. Indeed, interesting approaches to study 
pro-apoptotic and anti-apoptotic processes at the level of  
the liver are the use of  in vitro models to explore the mo-
lecular events, tissue expression and circulating levels of  
the single factors. The first procedure partially limits the 
translation to the human scenario, mainly when moving 
from FL to NASH, because NAFLD reflects the long-
lasting, complex dynamics orchestrated by various cells, 
such as adipocytes, β cells, muscle cells, macrophages and 
natural killer T cells. Apoptosis being a composite system 
regulated in a complex fashion with the contribution of  
many different factors, the expression of  a single protein 
in liver specimens gives only a snapshot of  a process that 
is hardly static. In favor of  the serum concentrations 
stands the fact that either the stimulatory or the counter-
regulatory circuits might eventually determine the net 
global effect of  a given component. In conditions of  
chronic inflammation or oxidative stress, as for metabolic 
syndrome (MS), it is conceivable that the entire network 
is in a long-term persistent state of  activation leading 
to increased circulating levels. In the serum of  NAFLD 
patients, cytochrome c, an indicator of  apoptosis-related 
mitochondrial damage, has been scarcely detected[4]. 
Among the anti-apoptotic factors, circulating levels of  
soluble Fas have been studied in some acute and chronic 
liver diseases[5,6]. The expression of  Bcl-2 in the liver tis-
sue of  NAFLD patients has been evaluated by real-time 
PCR or, alternatively, by immuno-histochemical staining, 
highlighting surprisingly different patterns. In fact, in pa-
tients with NASH the expression of  the Bcl-2 protein in 
liver specimens is mildly increased[7]. In contrast, in rats 
with high-fat diet-induced NASH, the hepatic expression 
of  Bcl-2 did not differ from that of  animals on control 
diet[8]. Similarly, no significant difference in the expres-
sion of  Bcl-2 in NASH and biopsy-proven FL patients 
was observed[2]. Other authors have shown that the tis-
sue expression of  this anti-apoptotic protein diminished 
with the advancement of  liver steatosis[9]. Recent data 
have shown that NAFLD patients with elevated gamma 
glutamyl-transpeptidase (γ-GT) activity have significantly 
higher Bcl-2 staining levels compared to patients evidenc-
ing normal γ-GT[10]. We firstly hypothesized that serum 
Bcl-2 levels reflect the steady state of  this anti-apoptotic 
protein. A recent study, showing that urinary Bcl-2 con-
centrations are elevated in females suffering from ovarian 
cancer regardless of  their creatinine levels or age[11], sup-
ports this hypothesis. A further confirmation is given by 
the fact that decreased apoptosis is in part associated with 
increased serum Bcl-2 levels in patients with melano-
ma[12]. Secondly, novel evidence suggests that low-grade 
chronic inflammation, in which spleen volume plays a key 
role[13], is the cause of  IR in O/O patients, whose serum 
levels of  soluble Fas interfere with the apoptotic path-
way[14]. Finally, serum levels of  Bcl-2 and cellular oxida-
tive stress have already been studied in patients with viral 
hepatitis, showing a close link[15]. On the other hand, a 
“metabolically benign obesity” which is not accompanied 
by IR has recently been postulated to exist in humans[16-18], 
although this hypothesis has been challenged by some 
authors[19]. As a consequence, some researchers have started 
considering NAFLD, independent of  its severity, as a 
divide between metabolically healthy O/O and metaboli-
cally unhealthy O/O (MUO)[20] individuals. Against this 
background, we felt the need to shed some light on the 
relationship between anti-apoptotic serum Bcl-2 concen-
trations and metabolic status, anthropometric parameters, 
inflammation indices, such as C-reactive protein (CRP) 
and spleen volume[13], as well as NAFLD severity in the 
vast complex of  O/O and MS, in young adults and mid-
dle aged individuals.
MATERIALS AND METHODS
This research was performed by initially screening 178 
consecutive subjects referred to our out-patient Meta-
bolic Unit with established (at least 4 years) O/O, from 
February 2006 to December 2009. The study was car-
ried out according to the principles of  the Declaration 
of  Helsinki and informed written consent was obtained 
from each patient.
Enrollment criteria 
Out of  the 178 initial participants 15 were excluded due 
to marked intestinal meteorism which made it difficult 
to perform abdominal ultrasound (first step to screen-
ing NAFLD), 16 patients because they had undergone 
steroid therapy (seven for bronchial asthma, five for 
rheumatoid arthritis, two for neuritis and two for inflam-
matory bowel disease), and 28 because they had received 
one or more drugs (i.e., aspirin, metformin, statins and 
Diagnosis
H FL NASH P value
Subjects (n) 21 43 41
Females 11 30 24    0.951
Age (yr) 19.1 ± 3.8      31.4 ± 13.9 35.6 ± 13  < 0.0012
Overweight   0   3   3  0.71
Obesity 1st grade   0 13   9  0.51
Obesity 2nd grade   0   9   6  0.61
Obesity 3rd grade   0 18 24    0.851
MS   0 24 36      0.0015
MUO   0 34 39    0.061
BMI
   F   23.8 ± 1.13      38.8 ± 8.24  37.8 ± 6.6  < 0.0012
   M 23.7 ± 0.6    38.6 ± 4.4    45.7 ± 10.5    0.013
WC (cm)
   F 86.3 ± 1.4    114.8 ± 15.7  117.3 ± 17.7      0.0012
   M 93.4 ± 2.3    121.2 ± 11.3  131.1 ± 15.1  < 0.0013
HOMA [median (range)] 1.77 (1.03-6)     2.3 (1.4-7.3)   4.1 (0.6-10.2)    < 0.00013
γ-GT U/L [median (range)]      33.1 (23.4-44.8) 40.5 (26-80)     54 (22.5-397)    < 0.00019
ALT U/L [median (range)] 27 (18-34)      36 (14-133)  40 (11-153)      0.0046
Uric acid   3.5 ± 0.4        5.1 ± 1.45    5.4 ± 1.4  < 0.0012
Ferritin
   F   84.6 ± 10.3  139.6 ± 76.          149.2 ± 69      0.0012
   M 166.8 ± 37.4    218.5 ± 121.    280 ± 103    0.014
Triglycerides     85 (66-121) 96 (51-290) 117 (51-386)     0.1610
HDL (mg/mL)
   F   63.6 ± 7.97      51.8 ± 9.38         50 ± 11.15      0.0012
   M 55.3 ± 8.4    50.8 ± 7.9     44 ± 4.4  < 0.0018
Triglycerides/HDL [median (range)]
   F      1.32 (1.16-1.49)     2.19 (1.18-6.5) 1.51 (1.07-7.6)      0.0046
   M    1.635 (1.39-1.75)     1.67 (1.25-2.7) 2.65 (1.25-8.8)    0.037
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fibrates) that may have altered their laboratory data. 
Fourteen others were excluded because of  the presence 
of  hepatic co-morbidities in their medical history (HCV 
infection, alcohol abuse), and finally twenty subjects were 
considered drop-outs, because they refused to undergo 
full laboratory-instrumental examinations. Eighty-four 
of  the 119 patients, with ultrasound findings of  “bright 
liver” and/or hyper-transaminasemia of  unknown ori-
gin and/or increase in γ-GT strictly in the absence of  
other acute or chronic liver disease, whose age was not 
advanced (Table 1), gave consent to liver biopsy and were 
then divided on the basis of  the histological results (see 
below) into two groups (43 with FL and 41 with NASH) 
that formed the final study population. Twenty lean 
subjects, apparently healthy and young, were chosen as 
controls to avoid any confounding factor with circulating 
levels of  Bcl-2 (see below).
Exclusion criteria
Any viral, autoimmune, metabolic liver disease (Wilson 
disease, hemochromatosis or antitrypsin deficiency) was 
ruled out by using appropriate testing, following the ac-
cepted diagnostic guidelines. Celiac disease was excluded 
by estimates of  IgA anti-tissue transglutaminase antibod-
ies. Alcohol abuse was ruled out, according to the DSM-
IV diagnostic criteria, by means of  screening tests such 
as MAST (Michigan alcohol screening test) and CAGE 
(Cut down, Annoyed, Guilty, and Eye opener), as well as 
random tests for blood alcohol concentration and the use 
of  a surrogate marker, e.g., Mean Corpuscular Volume. 
Patients on antihypertensive drugs maintained a balanced 
therapeutic regimen throughout the study.
Metabolic profile
The degrees of  obesity was established on the basis of  
BMI cut-off  points of  25-29.9, 30-34.9, 35-39.9 and > 
40 kg/m2, respectively. Visceral obesity was identified 
by measuring waist circumference (WC) at the midpoint 
between the lower border of  the rib cage and the iliac 
crest. MS was defined according to the revised Adults 
Treatment Panel Ⅲ (2001), and three or more criteria 
were considered: plasma glucose concentration of  at least 
Table 1  Clinical characteristics and laboratory data of the study population (mean ± SD)
1χ 2 test between fatty liver (FL) and non alcoholic steato hepatitis (NASH); 2analysis of variance (ANOVA) [significance between healthy (H) 
and FL and between H and NASH]; 3ANOVA (significance between H and FL, between H and NASH and also between FL and NASH); 
4ANOVA (significance between H and NASH); 5Pearson χ 2 (significance between FL and NASH); 6Kruskal-Wallis test (significance between 
H and FL and between H and NASH); 7Kruskal-Wallis test (significance between NASH and FL and between NASH and H); 8ANOVA (sig-
nificance between NASH and FL and between NASH and H); 9Kruskal-Wallis test (significance between H and FL, between H and NASH 
and also between FL and NASH); 10Kruskal-Wallis test. F: Females; M: Males; n: Number; H: Healthy; FL: Fatty liver; NASH: Non alcoholic 
steato hepatitis; ALT: Alaninamino transferase; γ-GT: γ-glutamil transferase; HDL: High density lipoprotein; HOMA: Homeostatic meta-
bolic assessment; BMI: Body mass index; MS: Metabolic syndrome; MUO: Metabolically unhealthy overweight/obese; WC: Waist circum-
ference.
Tarantino G et al . Bcl-2 and NAFLD
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100 mg/dL, WC > 88 cm, serum HDL concentration < 
50 mg/dL for women and < 40 mg/dL for men, blood 
pressure of  at least 130/85 mm Hg, and serum triglyc-
eride concentration of  at least 150 mg/dL. IR status was 
determined by the Homeostatic metabolic assessment 
(HOMA), which was assessed by the formula: fasting 
insulin (μU/mL) × fasting glucose (mg/dL)/405[21]. As 
a stringent measure of  IR, a value of  HOMA > 2 was 
introduced, according to the cut-off  value of  surrogate 
measures of  IR for MS in non-diabetic adults[22]. More-
over, as the repeated HOMA measurements presented 
high within-person variability in O/O patients, HOMA 
values were averaged on the basis of  at least five determi-
nations to avoid misclassification. When reporting triglyc-
erides values, only the data of  examinees who had fasted 
a minimum of  9 h before the morning examination were 
included to avoid false increases, averaging the results of  
at least two determinations made on different days. To 
avoid the high intra-individual variability the triglyceride/
HDL cholesterol ratio was evaluated (see below). MUO 
subjects were categorized in such a way in the presence 
of  IR, MS, high levels of  serum uric acid (UA),[23] and if  
their triglyceride/HDL cholesterol ratio was ≥ 1.65 (men) 
or ≥ 1.32 (women)[24].
Ultrasound evaluation
Ultrasonographic (US) measurements were performed 
by two operators, using a general electric vivid system. 
Spleen longitudinal diameter (SLD) was chosen to evalu-
ate spleen volume and was carried out by postero-lateral 
scanning. Maximum length (the optically greatest overall 
longitudinal dimension obtained from one of  the two 
poles) and cranio-caudal length (the optically maximal 
transversal dimension intercepting one of  the two poles) 
were measured; the resulting values were then averaged, 
since the two measurements do not always coincide. The 
classification of  “bright liver” or hepatic steatosis (HS) 
was based on the following scale of  hyper-echogenicity: 
0 = absent, 1 = light, 2 = moderate, 3 = severe, point-
ing out the difference between the densities of  the liver 
and the right kidney. Technically, echo intensity can be 
influenced by many factors, particularly by gain intensity. 
To avoid confounding factors that could modify echo 
intensity and thus bias comparisons, the mean brightness 
levels of  both the liver and the right kidney cortex were 
obtained on the same longitudinal sonographic plane. 
The levels of  brightness of  the liver and the right kidney 
were calculated three times directly from the frozen im-
ages.
Blood pressure measurements 
Systolic/diastolic blood pressure was the average of  three 
consecutive readings taken by the physician during the 
day, during the usual practice hours, after subjects had 
rested for 5 min in the sitting position.
Laboratory data
Serum triglycerides, HDL, basal insulin, ALT, γ-GT, UA, 
glycemia and ferritin were performed by in-house stan-
dard procedures. Hs-CRP values were determined by 
ELISA test, with reference values between 0.3 and 8.6 
mg/L in healthy men and between 0.2 and 9.1 mg/L in 
healthy women (BioCheck, Inc CA, United States). Bcl-2 
was determined using a Human Bcl-2 ELISA Kit (producer 
Bender MedSystems, Austria, EU) with a coefficient of  
variation ranging from 5.1 to 17.7, a sensitivity of  2.5 ng/
mL, an overall intra-assay coefficient of  8.6 and a refer-
ence interval calculated on 21 healthy subjects (Table 1) by 
the non-parametric percentile method (CLSI C28-A3) of  
7.4-22.6 ng/mL.
Liver histology
The diagnosis of  NASH was made when three of  the 
following five criteria were proven by liver biopsy: ste-
atosis, hepatocyte ballooning, lobular inflammation, 
portal inflammation and mallory bodies. Data on Mallory 
bodies were collected as inclusion criteria to pinpoint 
the accuracy of  diagnosis, but they were not used for 
evaluation. A 4-point scale for each of  the four follow-
ing criteria resulted in a sum score ranging from 0 to 12. 
Specifically, the scores were: Steatosis: 0 = None; 1 = Up 
to 33% of  acini, mainly macrovesicular; 2 = 34%-66% 
of  acini, commonly mixed steatosis; 3 = Over 66% of  
acini (panacinar), commonly mixed steatosis; Hepatocyte 
ballooning: 0 = None; 1 = Occasional in zone Ⅲ; 2 = 
Obvious in zone Ⅲ; 3 = Marked, predominantly in zone 
Ⅲ; Lobular inflammation: 0 = None; 1 = Scattered neu-
trophils, occasional mononuclear cells, 1 or 2 foci per 20
× objective; 2 = Neutrophils associated with ballooned 
hepatocytes, mild chronic inflammation, 3 or 4 foci per 
20 × objective; 3 = Acute and chronic inflammation, 
neutrophils may concentrate in zone Ⅲ, over 4 foci per 
20 × objective. Portal inflammation: 0 = None; 1 = Mild, 
some portal areas; 2 = Mild to moderate, most portal 
areas; 3 = Moderate to severe, most portal areas. Fibrosis 
was staged as follows: Stage 0 = None; Stage 1 = Zone 
Ⅲ perivenular, perisinusoidal (pericellular); Stage 2 = 
Stage 1 changes plus periportal fibrosis; Stage 3 = Bridg-
ing fibrosis; Stage 4 = Cirrhosis. Biopsy samples were 
taken within eight weeks prior to inclusion. FL was diag-
nosed when only steatosis was present, using the same 
grades previously reported[1-3]. The biopsy sample had to 
be at least 1.5 cm long with a minimum diameter of  0.8 
mm. Inclusion of  a NASH patient in the study required a 
sum score of  at least 6 points. 
Apoptosis detection 
Terminal deoxynucleotidyl transferase-mediated dUTP 
nick-end labeling (TUNEL) is a common method for 
detecting DNA fragmentation that results from apoptotic 
signaling cascades. We used the Click-iT® TUNEL Alexa 
Fluor® 647 Imaging Assay (Invitrogen). This method 
utilizes a dUTP modified with an alkyne, a small, bio-
orthogonal functional group that enables the nucleotide 
to be more readily incorporated by TdT than other modi-
fied nucleotides, including BrdUTP, biotin-dUTP or fluo-
Tarantino G et al . Bcl-2 and NAFLD
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rescein-dUTP. Detection is based on a click reaction, i.e., 
a copper catalyzed reaction between an azide and alkyne. 
Cells displaying TUNEL-labeled fluorescent nuclei 
were quantified by counting the number of  positive cells 
per high-power field. A total of  10 high-power fields were 
analyzed for each patient with excitation and emission 
wavelengths of  380 and 430 nm, respectively, using an 
inverted laser scanning confocal microscope (Carl Zeiss) 
equipped with a ×40 NA 1.4 lens. Data are expressed as 
the number/mm2 of  TUNEL-positive cells.
Statistical analysis
Age data, derived from a normally distributed popula-
tion [Kolmogorov-Smirnov test (K-S), P = 0.15], ferritin 
(K-S, P = 0.6), BMI (K-S, P = 0.2), WC (K-S, P = 0.18), 
SLD (K-S, P = 0.52), UA (K-S, P = 0.105) are given as 
mean plus SD. Variables not normally distributed, such 
as triglycerides (K-S, P = 0.0013), triglycerides/HDL 
(K-S, P ≤ 0.0001), HOMA (K-S, P = 0.0016), ALT 
(K-S, P = 0.0001), CRP (S-W, P = 0.001) are expressed 
as median (range). Grades at histology and US were con-
sidered ordinals and managed in the same way. The differ-
ence in medians was assessed by the Mann-Whitney test 
for independent samples. One-way analysis of  variance 
(ANOVA) was used to test the difference between the 
means of  several subgroups of  a variable (multiple test-
ing). If  the ANOVA test was positive (P < 0.05) then a 
Student-Newman-Keuls test for pairwise comparison of  
subgroups was performed. The ANOVA K-W test was 
used to calculate the differences between the medians of  
several subgroups of  a variable. If  K-W was positive (P < 
0.05) then a test for pairwise comparisons of  subgroups 
according to Conover was adopted. When adjusted for a 
covariate the ANOVA was transformed into ANCOVA 
and the significance was expressed as F-ratio. The Two-
Way Tables cross-tabulated one categorical row variable 
with one categorical column variable and the significance 
was set by the Pearson χ 2. When cross-tabulation was 
stratified for another dichotomous variable, the Mantel-
Haenszel χ 2 was carried out. Tracking the degree of  
association between single parameters, Spearman’s coeffi-
cient of  rank correlation (rho) for non uniform intervals 
was used. The Pearson’s coefficient (r) was employed to 
analyze the correlation between data derived from a nor-
mally distributed population. To predict a binary variable, 
the logistic regression (Enter Method), with relative Odds 
ratios and 95% confidence intervals (CI), was employed 
utilizing data from an independent variable. To assess 
the independent effect of  a quantitative variable on the 
prediction of  the values of  another variable, the linear 
regression analysis (least squares) was used, evaluating the 
standardized coefficient β (β) and t, which is a measure 
of  the precision with which the regression coefficient is 
measured. A tolerance of  less than 0.20 and/or a vari-
ance inflation factor of  5 and above indicated a multi-
colinearity problem. When confronted with the question 
of  how accurate a parameter was in identifying MUO 
cases, the discrimination was evaluated using receiver 
operating characteristic curve analysis (ROC), expressed 
as area under the ROC (AUC). A criterion or cut-off  was 
set and then sensitivity, specificity and positive likelihood 
ratio were estimated. Negative predictive value with the 
Bayes method was also calculated. The factor analysis was 
applied to detect the structure in the relationships among 
variables, selecting a subset of  variables having the high-
est correlations with the principal component factors. 
The Cattell Scree plot, with relative eigen values, was per-
formed to screen the real factors. Extraction of  the main 
components amounted to a variance maximizing (varimax) 
the rotation of  the original variable space. The critical 
value was calculated by doubling Pearson’s correlation co-
efficient for 1% level of  significance (5.152)/square root 
of  patients (84) minus 2, i.e., 0.568. The concordance 
correlation coefficient (ρc), which measures precision 
and accuracy, was adopted to evaluate the degree of  pair 
observations at US. Statistical analysis was performed 
operating on Systat 13 (Richmond, CA, United States) 
and MedCalc Version 11.4® (Frank Schoonjans) software 
packages.
RESULTS
Prevalence
The number of  individuals affected by being overweight, 
or by 1st, 2nd and 3rd grade obesity was comparable in 
NASH and FL populations and was well-balanced for 
gender. NASH patients were characterized by older age 
and a larger percentage of  MUO cases, having the larg-
est number of  MS among males (Mantel-Haenszel Chi-
Square P = 0.005), a greater BMI and a larger WC in 
males (ANOVA, F = 55.5, P = 0.0001 and F = 59.5, P = 
0.0001, respectively). Both insulin resistance and γ-GT 
activity were significantly higher in subjects diagnosed 
with NASH. Raised values of  ALT activity were hardly 
detected in NASH and FL patients. Men with NASH 
were affected by hyperferritinemia and had the lowest 
levels of  HDL and the highest triglycerides/HDL ratio. 
Serum uric acid was increased in FL and NASH patients 
without any difference between the two groups (Table 1). 
Apoptotic hepatocytes were significantly more numerous 
in NASH patients. NASH patients presented with larger 
spleens and augmented CRP concentrations compared 
with healthy subjects. In both populations of  NASH and 
FL the steatosis grade at histology was similar, so was the 
steatosis severity at US. Serum concentrations of  Bcl-2 
were significantly higher in the FL group than in the 
NASH group and patients of  both groups showed in-
creased values compared to healthy subjects (Table 2 and 
Figure 1). The significance did not change after adjusting 
the values of  Bcl-2 for γ-GT activity, with only the diag-
nosis being significant (ANCOVA, F = 14. 9, P = 0.0001).
Associations and prediction
The number of  apoptotic cells was significantly related to 
the anti-apoptotic Bcl-2 protein values (rh0 = 0.43, P = 
0.003) in FL patients but not in NASH ones (rh0 = 0.17, 
P = 0.27). Bcl-2 serum levels correlated well with the 
BMI values of  the whole population (rh0 = 0.55, P = < 
Tarantino G et al . Bcl-2 and NAFLD
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0.0001). The correlation between serum concentrations 
of  Bcl-2 and age was not significant (rh0 = 0.14, P = 0.15). 
Triglycerides/HDL ratio correlated well with WC in 
males (Pearson’s r = 0.51, P= 0.0008). γ-GT activity was 
associated with HOMA values (rh0 = 0.345, P = 0.0003), 
as was γ-GT with serum ferritin (rh0 = 0.22, P = 0.02). 
Bcl-2 concentrations were not related with either SLD or 
CRP values (rh0 = 0.10 and 0.13 with P = 0.3 and P = 
0.2, respectively). A non significant correlation was found 
between lobular inflammation and Bcl-2 levels in NASH 
patients (rh0 = -0.21, P = 0.2).
As to age, at linear regression, advancing years did 
not completely predict Bcl-2, β = -0.19, t = -2, P = 0.053 
(Figure 2A). UA predicted Bcl-2 values well, β = 0.35, t = 
3.8, P = 0.0002 (Figure 2B). 
At multiple regression analysis, HOMA, BMI and UA, 
in this sequence, best predicted Bcl-2 serum concentra-
tions, as higher IR corresponded to lower Bcl-2 values, 
whereas considerable BMI and elevated amount of  UA 
matched with higher Bcl-2 serum concentrations (Table 3). 
A sufficient prediction by low serum Bcl-2 values towards 
a higher rate of  MUOs was evidenced in logistic regres-
sion, OR = 0.98, CI 0.97-0.995, P = 0.004. Obviously, 
HOMA alone did not predict the status of  MUO, OR 1.38, 
CI 0.87-2.2.
Insulin resistance was closely related to inflammation 
and lipid asset; apoptosis did not seem related to age (Table 
4 and Figure 3). The concentrations of  serum Bcl-2 were 
not predicted by the number/mm2 of  TUNEL-positive 
cells in NASH patients (β = 0.013, t = 0.13, P = 0.9, Fig-
ure 4).
Reliability
Grades of  hepatic steatosis at US correlated with those at 
histology (rh0 = 0.45, P ≤ 0.0001). The AUC of  serum 
Bcl-2 only modestly predicted MUOs, i.e., 0.65%, CI 
0.53 to 0.75, with a sensitivity of  87% and a specificity 
of  50%, a positive likehood ratio of  1.73 using as cut-off  
106 ng/mL. The negative predictive value was 94% on 
the basis of  a disease (MS) prevalence in the population 
180
160
140
120
100
80
60
40
20
0
FL           Healthy        NASH
Bc
l-2
 (
ng
/m
L)
Diagnosis
Figure 1  Serum concentrations of Bcl-2 in the whole population. Kruskal-
Wallis test (significance between healthy and fatty liver (FL), between healthy 
and non alcoholic steato hepatitis (NASH) and also between FL and NASH); 
the highest median value was found in the FL group, P ≤ 0.001.
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Figure 2  Prediction of Bcl-2 serum levels by age and uric acid. A: Predic-
tion of antiapoptotic Bcl-2 protein serum concentrations by age, β = -0.19, t = 
-2, P = 0.0527; B: Prediction of antiapoptotic Bcl-2 protein serum concentrations 
by uric acid, β = 0.35, t = 3.8, P = 0.0002.
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Diagnosis
H FL NASH P value
Subjects (n)    21 43 41
Bcl-2 (ng/mL) 2.5 
(1.4-13)
25 
(2.5-168)
14 
(2.5-89)
< 0.0013
Hepatocyte ballooning grade NA NA 2 (1-3) NA
Steatosis score NA 2 (1-3) 2 (1-3)   0.492
Lobular inflammation grade NA NA 2 (1-3) NA
Portal inflammation grade NA NA 1 (1-3) NA
Fibrosis score NA NA 1 (1-2) NA
Apoptotic cells (n/mm2) NA 290 
(120-900)
780 
(110-1650)
  < 0.00012
HS at US grade NA 3 (0-3) 3 (0-3)     0.0642
CRP (mg/L) 0.9 
(0.4-5.4)
     3.9 
(0.1-21.1)
  5
(0.1-27)
      0.00011
Table 2   Serum concentrations of the anti-apoptotic protein 
Bcl-2,  histology features and inflammation parameters of the 
patients enrolled
1Kruskal-Wallis test [significance between healthy (H) and fatty liver (FL) 
and between H and non alcoholic steato hepatitis (NASH)]; 2Mann-Whit-
ney test; 3Kruskal-Wallis test (significance between H and FL, between H 
and NASH and also between FL and NASH). n: Number; H: Healthy; FL: 
Fatty liver; NASH: Non alcoholic steato hepatitis; NA: Not applicable; HS: 
Hepatic steatosis at ultrasound; US: Ultrasound; SLD: Spleen longitudinal 
diameter at ultrasound; CRP: C-reactive protein.
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of  20%. The intra-inter-observational reproducibility of  
the sonographic estimations for bright liver was high, 
with a ρχ of  0.93 and 0.89, respectively.
DISCUSSION
Medical reports emphasize that MS, of  which NAFLD is 
a further expression, is a major health problem in west-
ern countries. This research was conducted to establish 
whether serum Bcl-2 concentration could help clarify the 
role of  the anti-apoptotic process in this common dis-
ease, not to detect a further marker to diagnose NASH. 
The main finding was that low HOMA values predicted 
high Bcl-2 levels. Furthermore, high levels of  this anti-
apoptotic protein were found in patients with FL, which 
is also characterized by fewer apoptotic cells than the 
more severe form, i.e. NASH. First of  all, to avoid a pos-
sible bias[25], the authors stress that the population’s age 
did not affect anti-apoptotc protein Bcl-2 concentrations, 
as confirmed by regression equation and factor analysis. 
UA levels modestly prognosticate serum Bcl-2 concentra-
tions according to previous research on serum soluble 
Fas concentrations, which correlated significantly with 
UA levels[26]. These findings indicate that the antioxidant 
properties of  UA[27,28] are of  biological importance in vivo. 
Table 3   Prediction of anthropometric parameters, apoptosis 
detection and laboratory data by Bcl-2 concentrations
Effect β t P  value Tolerance
HOMA    -0.505  -4.27   0.000 0.440
HDL    0.22 1.4 0.16 0.242
WC    0.25 1.7 0.09 0.288
BMI    0.35   2.65   0.009 0.344
Triglycerides  -0.07  -0.17 0.86 0.040
Triglycerides/HDL    0.22 0.5 0.63 0.029
Uric acid   0.24 2.1 0.03 0.509
Ferritin  -0.15         -1.8 0.08 0.853
Apoptosis in NASH      0.013   0.13       0.9      1
NASH: Nonalcoholic steatohepatitis; BMI: Body mass index; HOMA: 
Homeostatic metabolic assessment; HDL: High density lipoprotein; tri-
glycerides and triglycerides/HDL were considered variables affected by 
collinearity; WC: Waist circumference; β: Beta, standardized coefficient; t: 
A measure of the precision with which the regression coefficient is mea-
sured. 
Table 4   Hidden relationships highlighted by factor analysis 
Factors 1 2
Bcl-2 -0.105  0.672
Age -0.348 -0.424
Apoptosis  0.293 -0.425
MS  0.606  0.011
BMI  0.564  0.528
WC  0.604  0.467
HOMA  0.781 -0.211
HDL -0.715  0.107
Triglycerides  0.521 -0.471
Triglycerides /HDL  0.698 -0.468
Uric Acid  0.554  0.520
Ferritin  0.279  0.064
ALT  0.545  0.097
 Γ-GT  0.074 -0.384
CRP  0.717 -0.274
SLD -0.202  0.282
HS at US  0.471  0.255
Steatosis  0.293  0.265
Insulin resistance is closely related to inflammation and lipid asset; apop-
tosis does not seem related to age. Percent of total variance explained for 
factor 1:26; for factor 2:14; the critical value is 0.568. HS: Hepatic steatosis; 
US: Ultrasound; SLD: Spleen longitudinal diameter at ultrasound; CRP: 
C-reactive protein; BMI: Body mass index; MS: Metabolic syndrome; ALT: 
Alaninamino transferase; γ-GT: γ-glutamyl transferase; HDL: High density 
lipoprotein; HOMA: Homeostatic metabolic assessment; WC: Waist cir-
cumference. 
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Figure 3  Variables clustered around factors. Homeostatic metabolic as-
sessment, C-reactive protein, triglycerides, triglycerides/high density lipoprotein 
ratio, ferritin and metabolic syndrome clustered around factor 1. HDL: High 
density lipoprotein. WC: Waist circumference; BMI: Body mass index; HOMA: 
Homeostatic metabolic assessment; HDL: High density lipoprotein; GGT: 
γ-glutamyl-transpeptidase; TRIG:Triglycerides; TRIGHDL: Triglycerides/high 
density lipoprotein; CRP: C-reactive protein; MS: Metabolic syndrome; FER: 
Ferritin; ALT: Alaninamino transferase; BMI: Body mass index; URICA: Uric 
acid; HSUS: Hepatic steatosis at ultrasound; SLD: Spleen longitudinal diameter.
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Figure 4  The concentration of serum Bcl-2 was not predicted by the num-
ber/mm2 of terminal deoxynucleotidyl transferase-mediated dUTP-biotin 
nick end labeling-positive cells. LCL: Low confidence limit; UCL: Upper con-
fidence limit; LPL: Low prediction  limit; UPL: Upper prediction Limit.
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Comparing the present results with relevant findings from 
other studies dealing with NASH, having found lower 
Bcl-2 concentrations, we support a low liver expression 
of  Bcl-2[28]. To reinforce this finding, apoptosis is recog-
nized as common in liver injury and may also contribute 
to tissue inflammation, fibrogenesis, and development of  
cirrhosis. The intensification of  inflammation in NAFLD 
is accompanied by an inhibition of  antiapoptotic Bcl-2[9]. 
Accordingly, in our study anti-apoptotic Bcl-2 protein 
concentrations showed an inverse trend towards lobular 
inflammation grades.
Contrary to current theory, hepatic steatosis appears 
to be a detoxification process, as FFAs are directly cy-
totoxic for the hepatocyte. The anti-apoptotic process, 
favoring the life span of  hepatocytes, and enhancing 
triglyceride formation, inhibits FFAs toxicity. Probably 
this is the reason for the major concentrations of  Bcl-2 
in FL. On the other hand, our laboratory findings do not 
necessarily mirror the processes happening in liver due to 
the lack of  correlation between apoptosis as well as in-
flammation and Bcl-2 levels in NASH patients. The strict 
association between IR, as well as BMI and Bcl-2 levels, 
could at least partially be explained as follows. All individ-
uals possess a maximum capacity for adipose expansion 
which is determined by both genetic and environmental 
factors. Once the limit of  adipose tissue expansion is 
reached, this ceases to store energy efficiently, with the 
subsequent accumulation of  lipids in other tissues. Ecto-
pic lipid accumulation in non-adipocyte cells causes lipo-
toxic insults including IR, apoptosis and inflammation. 
The adipose tissue expandability hypothesis states that a 
failure in the capacity of  adipose tissue expansion, rather 
than obesity per se, is the key factor linking positive en-
ergy balance and MS[29]. MUOs could represent subjects 
who are unable to sustain the expandability of  adipose 
tissue but are burdened by an abundant extra adipose 
tissue localization, for instance in liver. An alternative 
hypothesis suggests that a hyperleptinemic status, gener-
ally present in obese patients, might be involved. Now, 
since leptin reduces apoptosis, possibly via its ability to 
increase Bcl-2 and decrease Bax, altering the Bcl-2/Bax 
ratio, this status could explain the elevated concentra-
tions of  Bcl-2[30]. Some results show that IGF-1 increases 
mRNA levels and protein expression of  antiapoptotic 
Bcl-2[31-33] even though, in obese subjects all the main 
components of  the GH/IGF-1 axis might be widely 
variable[34]. In fact, serum IGF-1 levels inversely vary with 
severity of  hepatic steatosis[35]. Coming back to serum 
concentrations of  Bcl-2, a shift towards an antiapoptotic 
process could be protective in other areas[14]. By which 
mechanisms is Bcl-2 supposed to act? The endoplasmic 
reticulum (ER) is the main site for lipid biosynthesis in 
the cell. Disturbances of  this critical cellular function lead 
to ER stress. Several recent observations suggest a role 
for Bcl-2 at the ER. Bcl-2 located at the ER was shown 
to interfere with apoptosis induction. In fact, Bcl-2 at the 
ER may regulate calcium flow between the ER and the 
mitochondria. In addition, Bcl-2 is able to interact with 
the endoplasmic protein Bap31, thus avoiding caspase ac-
tivation at the ER. Bcl-2 may also hinder the function of  
ER located pro-apoptotic Bcl-2[36].
Limitations to this study are having detected a single 
protein in the apoptosis universe, and the use of  US as 
first screening method for O/O. In fact, although US has 
acceptable sensitivity and specificity, nevertheless, it has 
drawbacks that include its inaccuracy in exact quantifica-
tion of  fat accumulation, possibly excluding patients with 
light hepatic steatosis. Furthermore, the sample size is ap-
parently too small (the minimal required sample size per 
group with a type Ⅰ error of  0.05 and a Type Ⅱ error of  
0.05 for Bcl-2-analyzed as mean ± SD was calculated at 
42 patients). Finally, in our study there is some overlap in 
the Bcl-2 values seen in NASH and FL patients, the mini-
mum in both groups being 2.5 ng/mL(detection limit).
In conclusion, IR is strictly linked to serum Bcl-2 
values. Those were higher in FL than in NASH patients 
suggesting a protective role of  the anti-apoptotic process 
in liver and perhaps in other areas[37].
COMMENTS
Background
High serum levels of triglycerides/free fatty acids and insulin resistance are 
features of non-alcoholic fatty liver disease, an additional manifestation of the 
metabolic syndrome; the former is extremely common in patients suffering from 
overweight/obesity, and ranges from fatty liver to nonalcoholic steatohepatitis 
and liver cirrhosis. In determining nonalcoholic steatohepatitis, a role is thought 
to be played by free fatty acids that directly engage the core apoptotic machin-
ery. Moreover, increased apoptosis in liver specimens from nonalcoholic ste-
atohepatitis patients is associated with iron overload, which clearly correlates 
with insulin resistance and inflammation. Obviously, there is a certain balance 
between apoptosis and anti-apoptosis in determining the net effect on hepato-
cytes survival.
Research frontiers
The authors hypothesized that serum BCL-2 levels reflect the steady state of 
this anti-apoptotic protein.
Innovations and breakthroughs
The expression of Bcl-2 in the liver tissue of non-alcoholic fatty liver disease 
patients has previously been evaluated by real-time PCR or, alternatively, by 
immuno-histochemical staining, highlighting surprisingly different patterns. Se-
rum Bcl-2 increase is a likely response to the apoptotic process to improve sur-
vival of hepatocytes. If the response to the metabolic injury was good (increased 
serum levels of Bcl-2) probably the more severe form. i.e., non-alcoholic steato-
hepatitis would not develop. 
Applications
Metabolically unhealthy obese/overweight subjects could be further detected by 
Bcl-2 levels. By favoring the life span of hepatocytes, and enhancing triglyceride 
formation, the anti-apoptotic process probably inhibits free fatty acids toxicity in 
fatty liver.
Terminology
Bcl-2 (B-cell lymphoma 2) is the founding member of the Bcl-2 family of apopto-
sis regulator proteins encoded by the BCL2 gene.
Peer review
This is a very well carried out study and well written paper. However it needs a 
few clarifications from the authors.
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